Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 2,033 shares, a decline of 87.4% from the December 15th total of 16,171 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 6,747 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 6,747 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are short sold.

Global X Genomics & Biotechnology ETF Trading Up 0.7%

Shares of GNOM traded up $0.34 during mid-day trading on Tuesday, reaching $47.71. The company had a trading volume of 4,397 shares, compared to its average volume of 8,462. Global X Genomics & Biotechnology ETF has a fifty-two week low of $27.20 and a fifty-two week high of $48.92. The firm has a fifty day simple moving average of $45.67 and a 200-day simple moving average of $40.59. The stock has a market cap of $53.92 million, a price-to-earnings ratio of -20.38 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were given a dividend of $0.5912 per share. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is -26.50%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Flow Traders U.S. LLC grew its position in Global X Genomics & Biotechnology ETF by 52.4% in the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after acquiring an additional 82,063 shares in the last quarter. Insight Advisors LLC PA grew its holdings in Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock valued at $503,000 after purchasing an additional 19,319 shares in the last quarter. Sei Investments Co. increased its stake in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after buying an additional 12,105 shares during the period. Creative Financial Designs Inc. ADV lifted its holdings in Global X Genomics & Biotechnology ETF by 86.7% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock worth $188,000 after buying an additional 10,358 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.